

Resource Summary Report

Generated by [kravitz2](#) on Aug 17, 2026

Hu CD4 BUV496 SK3 100Tst

RRID:AB_2870220

Type: Antibody

Proper Citation

BD Biosciences Cat# 612936, RRID:AB_2870220

Antibody Information

URL: http://antibodyregistry.org/AB_2870220

Proper Citation: BD Biosciences Cat# 612936, RRID:AB_2870220

Target Antigen: CD4

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Flow - Surface

Antibody Name: Hu CD4 BUV496 SK3 100Tst

Description: This monoclonal targets CD4

Target Organism: Human

Clone ID: clone SK3 (also known as Leu3a)

Antibody ID: AB_2870220

Vendor: BD Biosciences

Catalog Number: 612936

Alternative Catalog Numbers: 612937

Record Creation Time: 20250820T000237+0000

Record Last Update: 20250820T071202+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD4 BUV496 SK3 100Tst.

No alerts have been found for Hu CD4 BUV496 SK3 100Tst.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Mossi Albiach A, et al. (2026) Tissue-reactive zonation of mesenchymal-like phenotypes in human glioblastoma. *Med (New York, N.Y.)*, 101228.

Lebrec H, et al. (2025) Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease. *iScience*, 28(5), 112447.

Tuomela K, et al. (2025) TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation. *Cell reports. Medicine*, 6(9), 102303.

Hasanov M, et al. (2025) Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. *Oncoimmunology*, 14(1), 2546402.

Olofsson A, et al. (2025) Adaptive immune responses against common viruses are sustained and functional in end-of-life patients. *iScience*, 28(3), 112082.

Bauman BM, et al. (2025) Dominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells. *The Journal of experimental medicine*, 222(6).

Gonnella G, et al. (2025) Immune profiling in subclinical secondary dengue-infected cases reveals adaptive immune signatures correlated to protection from severe dengue. *Cell host & microbe*, 33(7), 1191.

Benmebarek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. *Immunity*, 58(4), 926.

Mattingly CLR, et al. (2025) Human lung CD8+ tissue-resident memory T cell-derived interferon- γ orchestrates subset-specific antiviral programming in airway epithelial cells. *Immunity*, 58(12), 3006.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 156.

de Armas LR, et al. (2024) Accelerated CD8+ T cell maturation in infants with perinatal HIV infection. *iScience*, 27(5), 109720.

Adamo S, et al. (2023) Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. *Cell host & microbe*, 31(6), 928.

Bax CE, et al. (2023) Herbal supplement Spirulina stimulates inflammatory cytokine production in patients with dermatomyositis in vitro. *iScience*, 26(11), 108355.

Gao Y, et al. (2022) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. *Immunity*, 55(9), 1732.

Garcia-Valtanen P, et al. (2022) SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. *Cell reports. Medicine*, 3(6), 100651.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. *Immunity*, 54(6), 1257.

Lam AJ, et al. (2021) Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity. *Cell reports*, 36(5), 109494.

Brouwer PJM, et al. (2021) Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. *Cell*, 184(5), 1188.